STT-003 is under clinical development by Stcube and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how STT-003’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

STT-003 overview

STT-003 is under development for the treatment of head and neck cancer, melanoma, colorectal cancer and lung cancer. It acts by targeting BTN1A1.It is administered through intravenous route.

Stcube overview

Stcube is a developer and supplier of biopharmaceuticals. The company manufactures and supplies information technology products. It offers drug development, and novel anti cancer drugs system. STCube provides novel anticancer drugs for radiation sensitization and immune modulation. The company offers products which includes immuno modulator and upgraded targeted therapy. It provides antiviral treatment. It also provides research and development facilities to various universities and research institutes. It operates through its facilities located in South Korea and the US. STCube is headquartered in Seoul, South Korea.

For a complete picture of STT-003’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.